Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib and Radiation Therapy in Recurrent Gynecologic Cancers
NCT03968406Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2019
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 3 more, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 30 days. Started Sep 2019; status: recruiting.
02
Drugs
talazoparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)Cervical Cancer (CC)vaginal cancer
Beyond the preview
Go deeper on NCT03968406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03968406.